Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUXUS4.1 adjuvant disitamab vedotin plus radiotherapy versus gemcitabine plus carboplatin in HER2-expressing cisplatin-ineligible upper tract urothelial carcinoma
ChiCTR2600135326Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Shanxi Medical University
- Start
- Nov 2026
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in upper tract urothelial carcinoma (UTUC) comparing Disitamab vedotin plus radiotherapy with Gemcitabine plus carboplatin (2 arms). Primary endpoint: 3-year disease-free survival rate. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
disitamab vedotingemcitabinecarboplatin
03
Conditions
upper tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on ChiCTR2600135326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135326.